BIOMERICA financials
$2.30−3.76%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 May 31 | FY25 May 31 | FY24 May 31 | FY23 May 31 | FY22 May 31 | FY21 May 31 | FY20 May 31 | FY19 May 31 | FY18 May 31 | FY17 May 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.5M | $18.9M | $7.2M | $6.7M | $5.2M | $5.6M | $5.8M |
| Gross profit | $362.0K | $498.0K | $611.0K | $579.0K | $3.0M | $366.3K | $1.7M | $1.3M | $1.8M | $2.0M |
| Gross margin | 8.1% | 9.4% | 11.3% | 10.6% | 15.8% | 5.1% | 26.0% | 24.8% | 31.5% | 34.9% |
| Operating income | -$5.3M | -$5.1M | -$6.4M | -$7.1M | -$4.5M | -$7.5M | -$2.7M | -$2.4M | -$1.5M | -$954.6K |
| Net income | -$3.8M | -$5.0M | -$6.0M | -$7.1M | -$4.5M | -$7.4M | -$2.7M | -$2.4M | -$1.5M | -$908.6K |
| Net margin | −84.8% | −93.6% | −110.4% | −130.5% | −24.0% | −103.4% | −40.0% | −46.0% | −26.3% | −15.7% |
| Diluted EPS | $-1.30 | $-2.16 | $-2.84 | $-4.00 | $-2.88 | $-4.96 | $-2.08 | $-2.08 | $-1.36 | $-0.88 |
| EBITDA | -$5.2M | -$5.0M | -$6.3M | -$7.0M | -$4.2M | -$7.1M | -$2.6M | -$2.2M | -$1.3M | -$735.4K |
| Operating cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$479.0K | -$5.3M | -$4.3M | -$2.2M | -$1.2M | -$722.9K |
| Free cash flow | -$3.4M | -$3.8M | -$5.4M | -$5.5M | -$536.0K | -$5.4M | -$4.3M | -$2.3M | -$1.3M | -$818.9K |
| Diluted shares | 2.9M | 2.3M | 2.1M | 1.8M | 1.6M | 1.5M | 1.3M | 1.2M | 1.1M | 1.0M |
Balance sheet
| Period end | May 31 | May 31 | May 31 | May 31 | May 31 | May 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.3M | $2.4M | $4.2M | $9.7M | $5.9M | $4.2M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $6.8M | $5.9M | $9.3M | $14.5M | $11.4M | $11.8M |
| Total liabilities | $4.1M | $1.8M | $2.7M | $2.7M | $3.0M | $2.6M |
| Shareholders' equity | $2.6M | $4.1M | $6.6M | $11.7M | $8.3M | $9.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology